CHICAGO — AbbVie said on Monday that the Food and Drug Administration (FDA) has approved its drug for Parkinson’s disease.
Duopa, which is delivered directly into the small intestine with a portable infusion pump, treats symptoms such as tremors and muscle rigidity. The drug is already approved in Canada and dozens of other countries under the name Duodopa.
About 1 million Americans have Parkinson’s, a disease characterized by reduced levels of dopamine in the brain, which causes slowness, reduced mobility and stiffness, the Parkinson’s Disease Foundation says.
Duopa was approved as an orphan drug, used to treat rare diseases and usually approved with various incentives for the drugmaker.
Most Read Nation & World Stories
- FBI warned of large-scale nationwide protests by Trump supporters, but they fail to materialize
- Man lived inside Chicago's O’Hare airport for 3 months before detection, prosecutors say
- Trump prepares to offer clemency to more than 100 people in final hours in office
- Biden expected to cancel Keystone XL pipeline permit on first day
- Fauci says federal approval of Johnson & Johnson, AstraZeneca COVID-19 vaccines is ‘weeks away’
“There is unmet need for treatment options for patients with advanced Parkinson’s disease,” said Dr. C. Warren Olanow, lead investigator of the Duopa pivotal trial. “As the disease advances, it can be difficult to control motor features.”
Parkinson’s is characterized by reduced levels of the hormone dopamine in the brain, which leads to poor mobility, slowness and stiffness.